[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. (2020)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s00259-019-04532-z
PubMed Identifier: 31754793
Publication URI: http://europepmc.org/abstract/MED/31754793
Type: Journal Article/Review
Volume: 47
Parent Publication: European journal of nuclear medicine and molecular imaging
Issue: 5
ISSN: 1619-7070